Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9564565 | 1.00 | TK1 (0.52) | TK1TYMS | |
| SCHEMBL60737 | 1.00 | TK1 (0.52) | TK1TYMS | |
| SCHEMBL4626081 | 0.93 | TK1 (0.55) | TK1 | |
| SCHEMBL5086844 | 0.90 | TK1 (0.47) | TK1TYMS | |
| SCHEMBL5486404 | 0.90 | LMNA (0.47) | TK1TYMS | |
| SCHEMBL8426287 | 0.90 | TK1 (0.45) | TK1TYMS | |
| SCHEMBL8999406 | 0.90 | TK1 (0.45) | TK1 | |
| SCHEMBL1501551 | 0.90 | TYMS (0.44) | TK1TYMS | |
| SCHEMBL2027058 | 0.89 | LMNA (0.50) | TK1TYMS | |
| SCHEMBL8892073 | 0.89 | TYMS (0.43) | TK1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020142414-A1 | Process for the preparation of protease inhibitors | UCP GEN-PHARMA AG (CH) | 2002-10-03 | — | — | US | disclosed |
| US-6410272-B1 | GENERATION OF HURIDIN COMPOUNDS; OBTAIN YEAST CELLS, TRANSFORM WITH VECTORS CODING HURIDIN COMPOUNDS, ISOLATE HURIDIN COMPOUND | CIBA-GEIGY CORPORATION A CORP. OF NEW YORK | 2002-06-25 | — | — | US | disclosed |
| US-6342373-B1 | ACETYL DERIVATIVES OF AMINO ACID SEQUENCES, CULTURES OF ESCHERICHIA OR SACCHAROMYCES AND EXPRESSION VECTORS | UCP GEN-PHARMA AG (CH) | 2002-01-29 | — | — | US | disclosed |
| US-5728549-A | GENE EXPRESSION VECTORS WITH CONTROLLING SEQUENCES OF DNA | NOVARTIS CORPORATION (US) | 1998-03-17 | — | — | US | disclosed |
| US-5422249-A | Polypeptides | CIBA-GEIGY CORPORATION (US) | 1995-06-06 | — | — | US | disclosed |
| EP-0225633-B1 | PRODUCTION OF THROMBIN INHIBITORS | CIBA-GEIGY AG (CH) | 1992-08-12 | — | — | EP | disclosed |
| EP-0188400-B1 | OLIGOPEPTIDES, INTERMEDIATES AND PROCESS FOR THEIR PREPARATION | CIBA-GEIGY AG (CH) | 1992-07-08 | — | — | EP | disclosed |
| EP-0168342-B1 | PROCESS FOR THE PREPARATION OF THROMBIN INHIBITORS | CIBA-GEIGY AG (CH) | 1991-07-03 | — | — | EP | disclosed |
| EP-0146785-B1 | PROCESS FOR THE PREPARATION OF PROTEASE INHIBITORS | CIBA-GEIGY AG (CH) | 1990-02-07 | — | — | EP | disclosed |
| US-4720483-A | Oligopeptides and intermediates and processes for their manufacture | CIBA-GEIGY CORPORATION (US) | 1988-01-19 | — | — | US | disclosed |
| EP-0225633-A2 | Production of thrombin inhibitors | CIBA-GEIGY AG (CH) | 1987-06-16 | — | — | EP | disclosed |
| EP-0188400-A2 | Oligopeptides, intermediates and process for their preparation | CIBA-GEIGY AG (CH) | 1986-07-23 | — | — | EP | disclosed |
| EP-0168342-A1 | Process for the preparation of thrombin inhibitors | CIBA-GEIGY AG (CH) | 1986-01-15 | — | — | EP | disclosed |
| EP-0146785-A1 | Process for the preparation of protease inhibitors | CIBA-GEIGY AG (CH) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142414-A1 | Process for the preparation of protease inhibitors | EGLN2, EGLN1, PREP | TK1 2634/4885TYMS 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.